Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 54.35, which offers good timing for buyers.
  • The close medium term support offers good timing for purchasing the stock.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The group usually releases earnings worse than estimated.
  • With an enterprise value anticipated at 3.9 times the sales for the current fiscal year, the company turns out to be overvalued.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
MERCK AND COMPANY-3.02%148 618
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%222 939
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 036
AMGEN4.92%132 428
BRISTOL-MYERS SQUIBB COMPAN..7.60%108 890
NOVO NORDISK A/S-4.17%103 898
ABBOTT LABORATORIES3.36%102 678
SANOFI-9.46%100 767
BAYER-5.85%100 069
GLAXOSMITHKLINE-2.00%91 716
ELI LILLY AND COMPANY-8.61%85 390
ASTRAZENECA-7.21%84 103
CELGENE CORPORATION-10.14%70 622
ALLERGAN PLC-2.56%53 014
More Results
Financials ($)
Sales 2018 41 703 M
EBIT 2018 13 718 M
Net income 2018 8 465 M
Debt 2018 13 842 M
Yield 2018 3,52%
P/E ratio 2018 16,80
P/E ratio 2019 13,51
EV / Sales 2018 3,90x
EV / Sales 2019 3,75x
Capitalization 149 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart MERCK AND COMPANY
Duration : Period : Day
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Duration : Period : Week
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders